查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年的电脑模拟临床试验市场预测：按治疗领域、阶段、应用、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383360

到 2030 年的电脑模拟临床试验市场预测：按治疗领域、阶段、应用、最终用户和地区进行的全球分析

In Silico Clinical Trials Market Forecasts to 2030 - Global Analysis By Therapeutic Area, Phase, Application, End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球 In Silico 临床试验市场规模为 32.3 亿美元，预计到 2030 年将达到 60.6 亿美元，预测期内年复合成长率为 9.4%。

In Silico 临床试验，也称为虚拟临床试验或计算临床试验，是製药和医疗保健行业中使用的基于电脑的建模和模拟的一种型态。 In Silico 临床试验使用计算技术和数学模型来模拟临床试验、药物开发和患者对药物反应的各个方面。 In Silico 临床试验透过在进行人体或动物测试之前提供有价值的见解，减少了大规模且昂贵的物理测试的需要，加速了药物开发并优化了治疗策略，旨在提高患者的安全。

根据欧洲药品管理局（欧盟）统计，EU/EEA每年核准超过4000项临床试验，其中60%由製药公司赞助，40%由非商业赞助商赞助。

提高病人安全

In Silico 临床试验是一种药物开发的变革性方法，透过电脑模拟取代或补充传统的人体临床试验。这种方法大大降低了与人体实验药物测试相关的风险。 In Silico 研究透过使用虚拟患者模型来评估潜在的副作用、药物交互作用和患者特异性反应，从而提高候选药物的安全性。此外，此类测试使製药公司能够改进药物配方并最佳化给药，以最大限度地减少副作用并确保患者的更大安全。由于病患安全是製药业的重中之重，In Silico 临床试验已成为提高整个药物开发製程安全性的强大工具，使其成为市场成长和普及的关键驱动力。

跨学科问题

多学科挑战是 In Silico 临床试验市场的主要抑制因素。 In Silico 临床试验需要来自不同领域的专家的合作，包括生物学、化学、药理学、资料科学和电脑工程。有效地交流和整合这些领域的知识是复杂的，并且可能导致误解、资料不相容和误解。这些跨学科的挑战减缓了研究和开发工作，阻碍了电脑模拟方法的采用，并且需要加强协调和标准化，以充分发挥这种创新方法在药物开发方面的潜力。

人工智慧和机器学习技术的进步

人工智慧 (AI) 和机器学习 (ML) 技术的进步为 In Silico 临床试验市场创造了重大机会。这些技术透过预测患者反应、优化候选药物和识别潜在副作用来提高电脑临床试验的精确度。此外，人工智慧和机器学习将促进新治疗标靶的发现和现有药物的重新利用，从而减少研究所需的时间和成本。随着这些技术的不断发展，电脑模拟临床试验市场将受益于效率的提高、药物开发成功率的提高以及更有针对性和更有效的治疗方法的潜力，最终将彻底改变製药业。

缺乏标准化协议和法律规范

In Silico 测试依赖于计算模型和模拟，并且没有普遍接受的标准，这可能会导致结果的变化和不一致。此外，法规机构可能难以建立明确的指导方针来评估和核准电脑研究，从而可能延迟其采用。缺乏标准化协议和法规引发了人们对 In Silico 测试结果可靠性和可信度的担忧，阻碍了製药和医疗保健行业的信任和接受。

COVID-19 的影响

COVID-19 大流行危机对多个行业造成了毁灭性影响。在此期间，使用电脑辅助药物开发导致了电脑测试市场的显着增长。随着学术界、生物技术和生物製药公司专注于预防冠状病毒疾病传播的研究和开发，使用计算模型进行电脑测试的需求正在增加。此外，随着病毒的突变率不断增加，科学家们正在努力寻找治疗方法。因此，研究和药物研发的重要性日益增加，刺激了医疗产品创新和法规批准的电脑模拟和模拟测试的增加。

预计肿瘤学领域将成为预测期内最大的领域

肿瘤学领域估计占最大份额。 In Silico 临床试验透过利用电脑模拟和建模加速癌症治疗方法的开发，为肿瘤学研究提供了突破性方法。这些模拟可以帮助评估候选药物的有效性、预测患者反应并最佳化治疗策略。鑑于癌症的复杂性和创新治疗方法的紧迫性，肿瘤学中的电脑模拟临床试验可显着节省成本和时间，并降低与传统临床试验相关的风险。该领域在推进精准医疗和个体化癌症治疗方面发挥关键作用，为改善癌症患者的治疗结果带来了希望。

製药和生物技术公司细分市场预计在预测期内复合年复合成长率最高

预计製药和生物技术公司部门在预测期内将出现良好成长。製药和生物技术公司正在使用电脑模拟方法来简化药物研发发现和开发过程。电脑模拟测试采用电脑模拟和建模来预测药物行为、优化配方并评估安全性和有效性。这种方法显着降低了研发成本并加快了新药的上市时间。它还能够更有效地探索候选药物，最大限度地减少昂贵且耗时的现场试验的需要。此外，製药和生物技术公司可以利用 In Silico 临床试验来加强其研究管道、推进技术创新，并最终为患者提供更安全、更有效的治疗方法。

比最大的地区

在估计期间，亚太地区占据最大的市场占有率。推动这一成长的因素包括强劲的製药和生物技术产业、庞大且多样化的患者群体以及支持性的法规环境。 In Silico 临床试验利用电脑模拟和建模来评估药物疗效和安全性，为传统临床试验提供了一种经济高效的替代方案。这种方法不仅加快了药物开发过程，而且还降低了与人体测试相关的成本和伦理问题。亚太地区对该技术的投资增加凸显了其成为领先的 In Silico 临床试验中心的潜力，有助于加快药物开发和改善医疗结果。

复合年复合成长率最高的地区：

预计北美在预测期内将实现盈利成长。北美是 In Silico 临床试验市场的重要中心。该地区拥有完善的製药和生物技术部门，并不断寻求创新解决方案来加速药物开发。 In Silico 临床试验利用电脑模拟来评估药物的安全性和有效性，由于其成本效益和速度而越来越受欢迎。大型製药企业和尖端研究机构的存在进一步推动了这项技术的采用。此外，北美的法律规范和医疗保健基础设施支持电脑临床试验的发展，使该地区成为透过计算建模和模拟来推进药物药物研发和开发的领导者。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球电脑模拟临床试验市场：依治疗领域

  • 肿瘤学
  • 心臟病学
  • 糖尿病
  • 感染疾病
  • 神经病学
  • 血液学
  • 皮肤科
  • 其他治疗领域

第6章全球电脑模拟临床试验市场：依阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第7章全球电脑模拟临床试验市场：依应用分类

  • 药物开发
  • 治疗最佳化
  • 医疗设备
  • 法规核准

第8章全球电脑模拟临床试验市场：依最终使用者分类

  • 製药和生物技术公司
  • 合约研究组织
  • 学术研究所
  • 其他最终用户

第9章全球电脑临床试验市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Certara, Inc.
  • Insilico Medicine, Inc.
  • Novadiscovery Sas
  • Dassault Systemes SE
  • The AnyLogic Company
  • GNS Healthcare Inc.
  • InSilicoTrials
  • Nuventra Pharma Sciences
  • Immunetrics Inc.
  • Abzena Ltd.
  • Clarivate
  • Evotec
  • Aitia
  • Allucent
  • Acellera Ltd.
Product Code: SMRC24210

According to Stratistics MRC, the Global In Silico Clinical Trials Market is accounted for $3.23 billion in 2023 and is expected to reach $6.06 billion by 2030 growing at a CAGR of 9.4% during the forecast period. In silico clinical trials, also known as virtual or computational clinical trials, are a form of computer-based modeling and simulation used in the pharmaceutical and healthcare industries. They involve the use of computational techniques and mathematical models to simulate various aspects of clinical trials, drug development, and patient responses to medications. In silico clinical trials aim to reduce the need for extensive and costly physical trials, accelerate drug development, optimize treatment strategies, and enhance patient safety by providing valuable insights before advancing to human or animal testing.

According to the European Medicines Agency - European Union, in the EU / EEA, more than 4,000 clinical trials are authorised each year, of which 60% of clinical trials are sponsored by the pharma industry and 40% by non-commercial sponsors.

Market Dynamics:

Driver:

Improved patient safety

In silico trials offer a transformative approach to drug development by replacing or supplementing traditional human trials with computer simulations. This method significantly reduces the risks associated with experimental drug testing on human subjects. In silico studies improve the safety profile of novel drug candidates by enabling the evaluation of possible side effects, drug interactions, and patient-specific responses through the use of virtual patient models. Furthermore, these trials enable pharmaceutical companies to refine drug formulations and optimise dosages to minimise side effects and ensure a higher level of safety for patients. As patient safety is a paramount concern in the pharmaceutical industry, in silico clinical trials provide a powerful avenue for enhancing the overall safety of drug development processes, making them a pivotal driver in the market's growth and adoption.

Restraint:

Interdisciplinary challenges

Interdisciplinary challenges serve as a significant restraint in the in silico clinical trial market. In silico trials require collaboration between experts from diverse fields, including biology, chemistry, pharmacology, data science, and computer engineering. Effective communication and integration of knowledge from these disciplines can be complex, potentially leading to misinterpretations, data incompatibility, or misunderstandings. These interdisciplinary challenges may slow down research and development efforts, hinder the adoption of in silico methods, and necessitate enhanced coordination and standardisation to unlock the full potential of this innovative approach in drug development.

Opportunity:

Advancements in artificial intelligence and machine learning technologies

Advancements in artificial intelligence (AI) and machine learning (ML) technologies present a significant opportunity in the in silico clinical trials market. These technologies enhance the precision of in silico clinical trials by predicting patient responses, optimising drug candidates, and identifying potential adverse effects. Furthermore, AI and machine learning empower the discovery of new therapeutic targets and the repurposing of existing drugs, reducing the time and cost required for research. As these technologies continue to evolve, the in silico clinical trials market stands to benefit from increased efficiency, improved success rates in drug development, and the potential for more tailored and effective treatments, ultimately revolutionising the pharmaceutical industry.

Threat:

Lack of standardized protocols and regulatory frameworks

In silico trials rely on computational models and simulations, and the absence of universally accepted standards can lead to variability and inconsistency in the results. Moreover, regulatory bodies may struggle to establish clear guidelines for evaluating and approving in silico trials, potentially delaying their adoption. The lack of standardised protocols and regulations raises concerns about the credibility and reliability of in silico trial outcomes, hindering trust and acceptance within the pharmaceutical and healthcare industries.

COVID-19 Impact

The COVID-19 pandemic crisis had a devastating effect on several industries. The use of computers to aid in drug development during this time led to a notable increase in the in-silico trial market. Because academics and biotechnological and biopharmaceutical businesses are working intensively on R&D for preventing the coronavirus disease from spreading, there is a greater need for in silico trials that use computational modelling. Furthermore, Scientists are working hard to find a cure for the COVID-19 pandemic as a result of the virus' rising mutation rate. As a result, the importance of research and drug discovery was increased, which in turn fueled the rise of the in silico computational modelling and simulation trials for medical product innovation and regulatory clearance.

The Oncology segment is expected to be the largest during the forecast period

The Oncology segment is estimated to hold the largest share. In silico clinical trials offer a groundbreaking approach to oncology research by utilising computer simulations and modelling to accelerate the development of cancer treatments. These simulations help assess drug candidates' efficacy, predict patient responses, and optimise treatment strategies. Given the complexity of cancer and the urgency for innovative therapies, in silico clinical trials in oncology offer significant advantages in terms of cost and time savings, as well as reduced risks associated with traditional clinical trials. This segment plays a pivotal role in advancing precision medicine and personalised cancer treatments, offering hope for improved outcomes for cancer patients.

The Pharmaceutical and Biotechnology Companies segment is expected to have the highest CAGR during the forecast period

The Pharmaceutical and Biotechnology Companies segment is anticipated to have lucrative growth during the forecast period. Pharmaceutical and biotechnology companies utilise in silico methods to streamline drug discovery and development processes. In silico trials employ computer simulations and modelling to predict drug behaviour, optimise formulations, and assess safety and efficacy. This approach significantly reduces research and development costs and expedites the time it takes to bring new drugs to market. It also enables a more efficient exploration of drug candidates, minimising the need for costly and time-consuming physical trials. Moreover, Pharmaceutical and biotechnology companies leverage in silico clinical trials to enhance their research pipelines, increase innovation, and ultimately deliver safer and more effective therapies to patients.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. Factors driving this growth include a robust pharmaceutical and biotechnology industry, a large and diverse patient population, and a supportive regulatory environment. In silico clinical trials, which utilise computer simulations and modelling to assess drug efficacy and safety, offer cost-effective and efficient alternatives to traditional clinical trials. This approach not only accelerates the drug development process but also reduces costs and the ethical concerns associated with human trials. The Asia-Pacific region's increasing investment in this technology highlights its potential to become a key hub for in silico clinical trials, contributing to faster drug development and improved healthcare outcomes.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America is a prominent hub in the in silico clinical trials market. The region boasts a well-established pharmaceutical and biotechnology sector, which continually seeks innovative solutions to expedite drug development. In silico clinical trials, which utilise computer-based simulations to assess drug safety and efficacy, are gaining traction due to their cost-efficiency and speed. The presence of major pharmaceutical companies and cutting-edge research institutions further drives the adoption of this technology. Additionally, North America's regulatory framework and healthcare infrastructure support the growth of in silico clinical trials, positioning the region as a leader in advancing drug discovery and development through computational modelling and simulations.

Key players in the market

Some of the key players in the In Silico Clinical Trials Market include: Certara, Inc., Insilico Medicine, Inc., Novadiscovery Sas, Dassault Systemes SE, The AnyLogic Company, GNS Healthcare Inc., InSilicoTrials, Nuventra Pharma Sciences, Immunetrics Inc., Abzena Ltd., Clarivate, Evotec, Aitia, Allucent and Acellera Ltd.

Key Developments:

In March 2022, QuantHealth partnered with 4P-Pharma to conduct AI-based in-Silico clinical trial simulations. In collaboration, the partnership would perform in silico clinical trials of their lead therapeutic candidates. The in-silico simulation of the phase II clinical trial of 4P004, a first-in-class disease-modifying osteoarthritis medication (DMOAD) developed by 4PPharma's spin-off, would kick off this comprehensive alliance.

In February 2022, IonsGate Preclinical Services and InSilicoTrials teamed up to revolutionize drug development. To digitalize IonsGate's drug development methods, InSilicoTrials would deliver a sophisticated modeling and simulation technology. This would reduce the cost and duration of preclinical testing while improving the safety of novel compounds.

Therapeutic Areas Covered:

  • Oncology
  • Cardiology
  • Diabetes
  • Infectious Disease
  • Neurology
  • Hematology
  • Dermatology
  • Other Therapeutic Areas

Phases Covered:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Applications Covered:

  • Drug Development
  • Treatment Optimization
  • Medical Devices
  • Regulatory Approval

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In Silico Clinical Trials Market, By Therapeutic Area

  • 5.1 Introduction
  • 5.2 Oncology
  • 5.3 Cardiology
  • 5.4 Diabetes
  • 5.5 Infectious Disease
  • 5.6 Neurology
  • 5.7 Hematology
  • 5.8 Dermatology
  • 5.9 Other Therapeutic Areas

6 Global In Silico Clinical Trials Market, By Phase

  • 6.1 Introduction
  • 6.2 Phase I
  • 6.3 Phase II
  • 6.4 Phase III
  • 6.5 Phase IV

7 Global In Silico Clinical Trials Market, By Application

  • 7.1 Introduction
  • 7.2 Drug Development
  • 7.3 Treatment Optimization
  • 7.4 Medical Devices
  • 7.5 Regulatory Approval

8 Global In Silico Clinical Trials Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical and Biotechnology Companies
  • 8.3 Contract Research Organizations
  • 8.4 Academic and Research Institutes
  • 8.5 Other End Users

9 Global In Silico Clinical Trials Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Certara, Inc.
  • 11.2 Insilico Medicine, Inc.
  • 11.3 Novadiscovery Sas
  • 11.4 Dassault Systemes SE
  • 11.5 The AnyLogic Company
  • 11.6 GNS Healthcare Inc.
  • 11.7 InSilicoTrials
  • 11.8 Nuventra Pharma Sciences
  • 11.9 Immunetrics Inc.
  • 11.10 Abzena Ltd.
  • 11.11 Clarivate
  • 11.12 Evotec
  • 11.13 Aitia
  • 11.14 Allucent
  • 11.15 Acellera Ltd.

List of Tables

  • Table 1 Global In Silico Clinical Trials Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 3 Global In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 4 Global In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 5 Global In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 6 Global In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 7 Global In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 8 Global In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 9 Global In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 10 Global In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 11 Global In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 12 Global In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 13 Global In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 14 Global In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 15 Global In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 16 Global In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 18 Global In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 19 Global In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 20 Global In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 21 Global In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 Global In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 23 Global In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 24 Global In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 25 Global In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 26 North America In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 28 North America In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 29 North America In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 30 North America In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 31 North America In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 32 North America In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 33 North America In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 34 North America In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 35 North America In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 36 North America In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 37 North America In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 38 North America In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 39 North America In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 40 North America In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 41 North America In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 42 North America In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 43 North America In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 44 North America In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 45 North America In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 46 North America In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 47 North America In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 48 North America In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 49 North America In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 50 North America In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 51 Europe In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 53 Europe In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 54 Europe In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 55 Europe In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 56 Europe In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 57 Europe In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 58 Europe In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 59 Europe In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 60 Europe In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 61 Europe In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 62 Europe In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 63 Europe In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 64 Europe In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 65 Europe In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 66 Europe In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 67 Europe In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 68 Europe In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 69 Europe In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 70 Europe In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 71 Europe In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 72 Europe In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 73 Europe In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 74 Europe In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 75 Europe In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Asia Pacific In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 78 Asia Pacific In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 79 Asia Pacific In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 80 Asia Pacific In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 81 Asia Pacific In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 82 Asia Pacific In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 83 Asia Pacific In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 84 Asia Pacific In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 85 Asia Pacific In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 86 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 87 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 88 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 89 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 90 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 91 Asia Pacific In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 92 Asia Pacific In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 93 Asia Pacific In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 94 Asia Pacific In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 95 Asia Pacific In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 96 Asia Pacific In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 Asia Pacific In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 98 Asia Pacific In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 99 Asia Pacific In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 100 Asia Pacific In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 South America In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 103 South America In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 104 South America In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 105 South America In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 106 South America In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 107 South America In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 108 South America In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 109 South America In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 110 South America In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 111 South America In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 112 South America In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 113 South America In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 114 South America In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 115 South America In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 116 South America In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 117 South America In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 118 South America In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 119 South America In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 120 South America In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 121 South America In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 122 South America In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 123 South America In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 124 South America In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 125 South America In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 126 Middle East & Africa In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 128 Middle East & Africa In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 129 Middle East & Africa In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 130 Middle East & Africa In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 131 Middle East & Africa In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 132 Middle East & Africa In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 133 Middle East & Africa In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 134 Middle East & Africa In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 135 Middle East & Africa In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 136 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 137 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 138 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 139 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 140 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 141 Middle East & Africa In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 142 Middle East & Africa In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 143 Middle East & Africa In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 144 Middle East & Africa In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 145 Middle East & Africa In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 146 Middle East & Africa In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 147 Middle East & Africa In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 148 Middle East & Africa In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 149 Middle East & Africa In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 150 Middle East & Africa In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)